Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Insights into Arbutus Biopharma's First Quarter Performance and Strategic Updates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court date scheduled for April 21, 2025 Strong financial position – expected cash runway ext